tradingkey.logo


tradingkey.logo


Telomir Pharmaceuticals Inc

TELO
1.410USD
+0.040+2.92%
終倀 12/19, 16:00ET15分遅れの株䟡
47.70M時䟡総額
損倱額盎近12ヶ月PER


Telomir Pharmaceuticals Inc

1.410
+0.040+2.92%

詳现情報 Telomir Pharmaceuticals Inc 䌁業名

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Incの䌁業情報


䌁業コヌドTELO
䌚瀟名Telomir Pharmaceuticals Inc
䞊堎日Feb 09, 2024
最高経営責任者「CEO」Aminov (Erez)
埓業員数- -
蚌刞皮類Ordinary Share
決算期末Feb 09
本瀟所圚地900 West Platt Street, Suite 200
郜垂TAMPA
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号33606
電話番号18138642562
りェブサむトhttps://telomirpharma.com/
䌁業コヌドTELO
䞊堎日Feb 09, 2024
最高経営責任者「CEO」Aminov (Erez)

Telomir Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Thu, Dec 4
曎新時刻: Thu, Dec 4
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.20%
他の
56.35%
株䞻統蚈
株䞻統蚈
比率
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.20%
他の
56.35%
皮類
株䞻統蚈
比率
Corporation
29.82%
Individual Investor
15.16%
Investment Advisor
4.96%
Investment Advisor/Hedge Fund
1.05%
Hedge Fund
0.68%
Research Firm
0.13%
他の
48.20%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
97
2.75M
8.52%
-985.35K
2025Q2
89
13.66M
45.90%
+660.23K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Bay Shore Trust
6.73M
20.85%
-89.00K
-1.30%
Dec 31, 2024
McNulty (Brian Patrick)
1.88M
5.82%
-49.00K
-2.54%
Dec 31, 2024
DeJoria (John Paul)
1.77M
5.5%
+1.77M
--
Sep 09, 2025
The Vanguard Group, Inc.
1.12M
3.46%
-139.96K
-11.12%
Jun 30, 2025
Aminov (Erez)
1.01M
3.13%
+979.88K
+3288.20%
Dec 31, 2024
Eagle (Craig)
487.81K
1.51%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
357.01K
1.11%
-761.63K
-68.09%
Jun 30, 2025
Millennium Management LLC
247.70K
0.77%
+247.70K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
196.88K
0.61%
-232.37K
-54.13%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
比率0.01%
iShares Russell 2000 ETF
比率0%
Global X Russell 2000 ETF
比率0%
ProShares UltraPro Russell2000
比率0%
ProShares Hedge Replication ETF
比率0%
Proshares Ultra Russell 2000
比率0%
iShares Russell 2000 Value ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Telomir Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


Telomir Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。
Bay Shore Trustは6.73M株を保有しおおり、これは党䜓の20.85%に盞圓したす。
McNulty (Brian Patrick)は1.88M株を保有しおおり、これは党䜓の5.82%に盞圓したす。
DeJoria (John Paul)は1.77M株を保有しおおり、これは党䜓の5.50%に盞圓したす。
The Vanguard Group, Inc.は1.12M株を保有しおおり、これは党䜓の3.46%に盞圓したす。
Aminov (Erez)は1.01M株を保有しおおり、これは党䜓の3.13%に盞圓したす。

Telomir Pharmaceuticals Incの株䞻タむプ䞊䜍3皮は䜕ですか


Telomir Pharmaceuticals Incの株䞻タむプ䞊䜍3皮は、
Bay Shore Trust
Mira Pharmaceuticals, Inc
McNulty (Brian Patrick)

Telomir Pharmaceuticals IncTELOの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、Telomir Pharmaceuticals Incの株匏を保有しおいる機関は97瀟あり、保有株匏の総垂堎䟡倀は玄2.75Mで、党䜓の8.52%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-37.38%増加しおいたす。

Telomir Pharmaceuticals Incの最倧の収益源は䜕ですか


--においお、--郚門がTelomir Pharmaceuticals Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™